Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2555 Target Snapshot

Thymidylate synthase · SINGLE PROTEIN · Escherichia coli K-12

Back to Search Search this target Browse approvals Evidence Card
74Compounds
20Assays
3Approved Drugs
73.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Thymidylate synthase shows approved-linked disease relevance led by adenocarcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P0A884. Start with adenocarcinoma, then reuse UniProt P0A884 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with adenocarcinoma, then reuse UniProt P0A884 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
adenocarcinoma

Thymidylate synthase shows approved-linked disease relevance led by adenocarcinoma. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with adenocarcinoma because it currently carries approved-linked support. Linked drugs include PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thymidylate synthase as ChEMBL target CHEMBL2555, mapped to UniProt P0A884. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thymidylate synthase
SINGLE PROTEIN · Escherichia coli K-12
As of 2026-09-13
ChEMBL target ID
CHEMBL2555
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P0A884
Thymidylate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Thymidylate synthase is the right protein anchor across sources, using UniProt P0A884 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why adenocarcinoma is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameThymidylate synthase
Target TypeSINGLE PROTEIN
OrganismEscherichia coli K-12
UniProtP0A884
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelThymidylate synthase
UniProt AccessionP0A884
Component TypeProtein
Sequence Length264 aa

Thymidylate synthase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Thymidylate synthase, mapped to UniProt P0A884. Sequence length is 264 aa.

Mapped IDP0A884
Review nameThymidylate synthase
OrganismEscherichia coli K-12
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Thymidylate synthase shows approved-linked disease relevance led by adenocarcinoma. 4 more disease programs remain visible in the same review block.

Approved-linked Approved
adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEMETREXED TROMETHAMINE
Approved-linked Approved
large cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEMETREXED TROMETHAMINE
Approved-linked Approved
lung large cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEMETREXED DIPOTASSIUM
Approved-linked Approved
mesothelioma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEMETREXED TROMETHAMINE
Approved-linked Approved
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugPEMETREXED TROMETHAMINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with adenocarcinoma because it currently carries approved-linked support. Linked drugs include PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseadenocarcinoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
Assay Mix

Activity Type Distribution

IC508.0
KI65.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL422395 7.22 IC50 60.0 Preclinical
CHEMBL422395 7.02 Ki 95.0 Preclinical
CHEMBL308223 6.6 Ki 250.0 Preclinical
CHEMBL2323403 6.52 Ki 300.0 Preclinical
CHEMBL67116 6.16 Ki 700.0 Preclinical
CHEMBL293670 6.16 Ki 700.0 Preclinical
CHEMBL294280 6.14 Ki 730.0 Preclinical
CHEMBL2323397 6.05 Ki 900.0 Preclinical
CHEMBL303950 6.0 Ki 1000.0 Preclinical
CHEMBL2323395 5.96 Ki 1100.0 Preclinical
Distribution

pChEMBL Value Distribution

16
5.0
17
5.5
5
6.0
2
6.5
2
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

20
Total Assays
55
Tested Compounds
1
Assay Types
Binding — 20 assays, 55 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 20 55 5.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine